Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockade

Luc Francis,Daniel McCluskey,Clarisse Ganier,Treasa Jiang,Xinyi Du-Harpur,Jeyrroy Gabriel,Pawan Dhami,Yogesh Kamra,Sudha Visvanathan,Jonathan N. Barker,Catherine H. Smith,Francesca Capon,Satveer K. Mahil

DOI: https://doi.org/10.1038/s41467-024-44994-w

IF: 16.6

2024-01-30

Nature Communications

Abstract:Abstract Biologic therapies targeting the IL-23/IL-17 axis have transformed the treatment of psoriasis. However, the early mechanisms of action of these drugs remain poorly understood. Here, we perform longitudinal single-cell RNA-sequencing in affected individuals receiving IL-23 inhibitor therapy. By profiling skin at baseline, day 3 and day 14 of treatment, we demonstrate that IL-23 blockade causes marked gene expression shifts, with fibroblast and myeloid populations displaying the most extensive changes at day 3. We also identify a transient WNT5A + /IL24+ fibroblast state, which is only detectable in lesional skin. In-silico and in-vitro studies indicate that signals stemming from these WNT5A + /IL24+ fibroblasts upregulate multiple inflammatory genes in keratinocytes. Importantly, the abundance of WNT5A + /IL24+ fibroblasts is significantly reduced after treatment. This observation is validated in-silico , by deconvolution of multiple transcriptomic datasets, and experimentally, by RNA in-situ hybridization. These findings demonstrate that the evolution of inflammatory fibroblast states is a key feature of resolving psoriasis skin.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem this paper attempts to address is understanding the specific mechanisms of IL-23 inhibitors in the early stages of psoriasis treatment. Although biologics targeting the IL-23/IL-17 axis have significantly improved the treatment outcomes for psoriasis, the mechanisms by which these drugs act in the early stages remain unclear. To fill this knowledge gap, researchers conducted longitudinal single-cell RNA sequencing (scRNA-seq) to analyze gene expression changes in skin samples from patients treated with IL-23 inhibitors at baseline, day 3, and day 14 of treatment.

Specifically, the study aims to:
1. **Reveal the early mechanisms of action of IL-23 inhibitors**: Through longitudinal analysis, determine which cell types and signaling pathways undergo significant changes in the early stages of treatment.
2. **Identify specific inflammatory cell states**: Particularly, identify a WNT5A+/IL24+ fibroblast state enriched in psoriatic lesions and explore its role in inflammation resolution.
3. **Validate changes in WNT5A+/IL24+ fibroblasts in other treatment regimens**: By analyzing other datasets, validate the trend of changes in this cell state across different treatment regimens, further confirming its importance in psoriasis treatment.

Through these studies, the authors hope to provide a deeper biological understanding of psoriasis treatment, thereby guiding future therapeutic strategies.